Group items matching

in title, tags, annotations or url

The FY18 VRP IIRA is intended to support studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma. Research projects may focus on any phase of research (e.g., basic, translational, applied, clinical, observational), excluding clinical trials. The research idea or solution should be innovative, novel, or a significant advancement over existing ideas or solutions, as applicable.

The purpose of this Funding Opportunity Announcement is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between drug resistance mutations present in minority variant viral populations and treatment outcomes, and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson's disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson's disease or enhancing the well-being of individuals experiencing the impact of the disease.

Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits a single application for the continuation of the AIDS and Cancer Specimen Resource (ACSR). The eligible applicant institutions (which are the two current NCI-supported ACSR lead institutions) are expected to maintain the cooperative group structure and the activities of the ACSR. The primary objective of the ACSR will be to acquire, store, and equitably distribute tumor tissues, biological fluids, and associated demographic data from patients with human immunodeficiency virus (HIV)-associated malignancies. In addition to serving acquired immunodeficiency syndrome (AIDS) and cancer researchers at large, the ACSR will specifically provide biorepository functions for another NCI supported initiative, the AIDS Malignancy Consortium (AMC). The AMC performs clinical trials research in the treatment and prevention of HIV-associated malignancies in the United States and Sub-Saharan Africa. As the AMC is currently expanding its agenda to include Latin America, it is expected that the ACSR will collaborate with the AMC to develop regional biorepository support for AMC activities in Latin American countries. The continuing ACSR must have appropriate strategies and capabilities to address several high priority areas of specimen acquisition including specific types of cancer (AIDS-defining as well as non-AIDS defining), types of biospecimens and accompanying clinical data, and biospecimens from geographic areas of interest.

Recent advances in endovascular thrombectomy and the extended time window for intervention in acute ischemic stroke patients that have salvageable brain tissue at the time of reperfusion, offer a new opportunity to reconsider neuroprotective agents as adjunctive therapies to extend the time window for reperfusion and to improve long-term functional outcome. The purpose of this funding opportunity announcement (FOA) issued by NINDS is to invite applications for network sites for the NIH Stroke Preclinical Assessment Network (SPAN).

This FOA invites new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components. CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans.

This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HIV-associated neurological disorders (HAND) in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.

The purpose of this FOA is to support the development of a Clinician-Scientists Transdisciplinary Aging Research (Clin-STAR) Coordinating Center that will organize activities and provide research resources for clinician-investigators across the United States who are focusing their careers on aging research. This FOA is intended to build upon the substantial investments made by NIA through the GEMSSTAR program and related career development efforts by supporting expanded activities to reach a broader community of clinician-investigators. The specific goals of this initiative are to convey scientific and research knowledge on aging research; foster networking and collaboration between clinician-scientist leaders in aging research and clinician-investigators across specialties who wish to focus on aging research; provide mentoring and career development support for emerging clinician-scientists committed to pursuing aging research in their clinical specialty or discipline; and advance transdisciplinary research projects in aging. Ultimately, the Clin-STAR Coordinating Center is intended to provide a multi-faceted national research platform leading to improved patient-centered care for older adults across specialties and disciplines.

This Funding Opportunity Announcement (FOA) invites research grant applications to study the cellular and molecular mechanisms delineating the neuropathophysiology of HAND in the setting of long-term combination antiretroviral therapy (cART) conditions using induced microglia and cerebral organoids generated from patient derived induced pluripotent stem cell (iPSC) lines.

The Michael J. Fox Foundation seeks applications with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care. Proposals must have a well-defined plan for moving toward clinical utility for Parkinson's disease (PD) patients. The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from non-PD indications. Part of our Edmond J. Safra Core Programs for PD Research, the Therapeutic Pipeline Program advances Parkinson's disease therapeutic and intervention development along the pre-clinical and clinical path (i.e., both drug and non-pharmacological therapeutics, including gene therapy, biological, surgical and non-invasive approaches).

The Michael J. Fox Foundation will award one-year to 18-month grants for studies that explore the role of astrocytes in Parkinson's disease (PD) pathology and the potential for astrocyte-focused therapeutics. The goals of this funding program are to further understanding of astrocyte biology in Parkinson's and to rationalize the pursuit of astrocyte-specific targets and/or pathways for the treatment of the disease. Preference will be given to applications that focus on or include the following: Role of astrocytes in initiating and/or propagating Parkinson's disease pathology, including alpha-synuclein spread, dopaminergic neuron death, inflammation and senescence Consequences of dysfunction and/or mutations of common PD targets, including alpha-synuclein, LRRK2, GBA, PRKN and PINK1 Manipulation of astrocyte activity and/or astrocyte-specific pathways to assess the potential of targeted astrocyte therapies on disease biology and/or symptoms Parkinson's disease models with high construct validity to human PD, including patient-derived material (such as iPSCs or cerebral organoids) and/or well characterized animal models and primary cells; Examination of human brain samples to answer specific hypotheses is also acceptable Targets, pathways and mechanisms proposed for investigation should have reasonable links to PD.

The Michael J. Fox Foundation will award one-year grants for research to advance the development, optimization and validation of assays to quantify oligomeric alpha-synuclein in human body fluids. These biofluids may include blood, cerebrospinal fluid, saliva and tears. Prior research suggests that alpha-synuclein quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response and/or patient stratification.  Immuno-assays should have a renewable source of the antibodies used. Optimization and/or adaptation of existent assays to different biological matrices will also be considered. Projects should propose to develop or optimize assays with superior performance in quantifying oligomeric alpha-synuclein and, at the end of the grant, should be able to present several performance parameters for further validation such as robustness, precision, trueness, uncertainty, limits of detection and quantification, dilutional linearity, parallelism, recovery, selectivity, and sample stability.

The PRP IIRA supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson's disease research and/or patient care. This award mechanism supports the full spectrum of research from basic science through clinical research that specifically focuses on scientific and clinical Parkinson's disease issues, which, if successfully addressed, have the potential to make a major impact in understanding, preventing, diagnosing, or treating Parkinson's disease or enhancing the well-being of individuals experiencing the impact of the disease.

Multiple groups using a variety of analytical techniques have reported the presence of different species of aSyn in biofluids such as blood, cerebrospinal fluid (CSF), saliva, and tears. Results suggest that aSyn levels may be different in Parkinson's disease compared to healthy controls. Thus, aSyn quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response, or patient stratification. At the same time, analysis of total aSyn in CSF collected in the Parkinson's Progression Markers Initiative (PPMI) study did not change significantly over the course of a year, indicating that total aSyn may not be a progression marker of PD. One of the hallmarks of PD is aSyn aggregation, and therefore oligomeric aSyn may represent a more pathologically relevant disease species to serve as a biomarker.

Astrocytes play a role in neurotransmitter regulation and trophic and metabolic support of neurons and help modulate vascular functioning. Current research on inflammation in the central nervous system is exploring the role of astrocytes beyond simple "reactive gliosis" and their interaction with microglia. There is emerging evidence that these cells could be participating in a novel drainage system in the brain. Recent evidence from Alzheimer's disease research has hinted that astrocytes could be propagators, and potentially initiators, of neuroinflammation. Postmortem examinations of brains from Parkinson's disease patients reveal "reactive" astrocytes and astrocytes that contain alpha-synuclein-positive inclusions.

The FY19 TBDRP Investigator-Initiated Research Award (IIRA) intends to support highly rigorous, high-impact studies that have the potential to make important contributions to Lyme disease and other tick-borne diseases research, patient care, and/or quality of life. This award mechanism promotes a wide range of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial to establish proof-of-principle for further development in future studies. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale that is established through logical reasoning, preliminary data, and critical review and analysis of the literature.

mportant aspects of this award mechanism include: * Impact: Applications should articulate both the short- and long-term impact of the proposed research. Projects must address one or more of the FY19 SCIRP IIRA Focus Areas. * Relevance to Military Health: Projects should be relevant to spinal cord-injured military Service members, Veterans, and/or their family members and caregivers. Collaboration with military and VA researchers and clinicians is encouraged. * Preliminary Data: Observations that drive a research idea may be derived from laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include preliminary and/or published data that are relevant to the mission of the SCIRP and support the proposed research project. IIRA applications may focus on any phase of research from basic through translational. Permitted research includes preclinical studies in animal models, research with human subjects, or human anatomical substances, as well as ancillary studies associated with an existing clinical trial. Applications including animal studies must include a clear justification for the animal model chosen including relevance to human SCI.

The SCIRP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of SCI. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.

This NOFO seeks to provide infrastructure support and technical assistance to Mozambican Ministry of Health (MOH) health clinics and facilities in order to scale-up HIV and TB services through PEPFAR. This NOFO will provide technical assistance to help address MOH infrastructure needs as well as providing overall alternative solutions to improving the health infrastructure either through renovations, pre-fabricated (pre-fab) structures, or equipment necessary for the improvement of HIV/AIDS and TB services across the clinical cascade. Sites for infrastructure support will be selected based on MOH and PEPFAR priorities. Health centers may require different infrastructure solutions which may include pre-fab structures for warehouses, pharmacies, laboratories, and medium-sized health units. Supported health facilities may be geographically dispersed throughout Mozambique and involve rural and urban areas. The accomplishment of these objectives will support the Government of Mozambique’s goal of promoting epidemic control through an increased facility maximum HIV patient capacity and will in turn facilitate the country’s HIV strategic goals.

NBF will award grants for investigator-initiated original research focused on any aspect of blood banking, transfusion medicine, cellular therapies, or patient blood management. Grants will support one- or two-year research projects with a maximum award of $75,000.